Blackstone's AI Diabetes Program Cuts Costs and Improves Care
TL;DR
Blackstone is testing an AI-powered program from startup Twin Health to help diabetics rely less on expensive drugs and reduce healthcare costs. The program is being tested with workers across 14 of Blackstone's portfolio companies and early results are promising. Patients with uncontrolled diabetes often move from older, lower-priced drugs onto newer pricey treatments made by Novo Nordisk A/S and Eli Lilly & Co. that can cost around $10,000 a year.
- Blackstone Slashes Its Ozempic Costs With AI Diabetes Program Bloomberg
- AI health care platform predicts diabetes with high accuracy but 'won't replace patient care' Fox News
- Blackstone Is Using AI to Control Diabetes and Slash Spending on Drugs Yahoo Finance
- Blackstone using AI to control employees’ diabetes and cut spending on expensive drugs | Mint Mint
Want the full story? Read the original reporting
Read on Bloomberg